Letter

Shared scheme for assessing drugs for multiple sclerosis: Cost effective provision of effective treatments for multiple sclerosis

BMJ 2003; 326 doi: 10.1136/bmj.326.7400.1212 (Published 29 May 2003)
Cite this as: BMJ 2003;326:1212.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jacqueline C Napier, associate medical director (jnapier@schering.co.uk),
  2. Richard Francis, country manager United Kingdom and Ireland,
  3. Glyn Wright, general manager
  1. Schering Health Care, Burgess Hill, West Sussex RH15 9NE
  2. Biogen, Maidenhead, Berkshire SL6 3UD
  3. Teva Pharmaceuticals, High Wycombe, Buckinghamshire HP13 7SS

    EDITOR—Sudlow and Counsell think that the UK government's risk sharing scheme for the provision of disease modifying drugs for multiple sclerosis (interferon beta and glatiramer acetate) may be flawed.1

    Firstly, the risk sharing scheme was introduced to ensure that the disease modifying drugs in question are acquired by the NHS in a cost effective manner, which will be reviewed by the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular